Piper Sandler analyst David Amsellem reiterates Amphastar Pharma (NASDAQ:AMPH) with a Overweight and maintains $71 price target.
Piper Sandler Reiterates Overweight on Amphastar Pharma, Maintains $71 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.